Bruce Johnson, MD
Bruce Johnson received his MD degree from the University of Minnesota in 1979, and his postgraduate training at the University of Chicago and the National Cancer Institute (NCI). After serving at NCI, where
he most recently headed the Lung Cancer Biology Section, he joined Dana-Farber in 1999. Dr. Johnson currently leads the Dana-Farber/Harvard Cancer Center Lung Cancer Program and is the chief clinical research officer at Dana-Farber Cancer Institute.
View Dr. Johnson's Harvard Catalyst Profile
Eliezer Van Allen, MD
Eliezer Van Allen, MD, is an assistant professor of Medicine at Harvard Medical School, a clinician at Dana-Farber/Partners Cancer Care, and an associate member at the Broad Institute of MIT and Harvard.
His research focuses on computational cancer genomics; the application of new technologies, such as massively parallel sequencing to precision cancer medicine; and resistance to targeted therapeutics.
As both a computational biologist and a medical oncologist, Dr. Van Allen has specific expertise in clinical computational oncology and the development of algorithms to analyze and interpret genomic data for clinically focused questions. Overall, his
research will make important contributions to the field of precision cancer medicine and resistance to targeted therapeutics via expertise and study in translational and clinical bioinformatics.
Originally from Los Angeles, CA, Dr. Van Allen studied Symbolic Systems at Stanford University, obtained his MD from UCLA, and completed a residency in internal medicine at UCSF before coming to Boston and completing a medical oncology fellowship in the
Dana-Farber/Partners Cancer Care program.
Visit Dr. Van Allen's lab website
Nikhil Wagle, MD
Nikhil Wagle, MD, is a medical oncologist at Dana-Farber Cancer Institute, an instructor in Medicine at Harvard Medical School, and an associated researcher at the Broad Institute of MIT and Harvard. His research
focuses on cancer genomics, resistance to targeted therapeutics, and cancer medicine. Dr. Wagle uses systematic genomic profiling approaches to comprehensively characterize tumor samples from patients with cancer in order to better understand the
molecular determinants of tumorigenesis; characterize mechanisms of therapeutic resistance; and identify actionable genomic alterations to aid with clinical decision-making.
Dr. Wagle's research also focuses on characterization of patients with cancer who develop resistance to targeted therapies. He previously identified activating mutations in MEK1, the kinase downstream from BRAF, as a novel mechanism
of resistance to the targeted therapy vemurafenib in metastatic melanoma. He continues to study mechanisms of resistance in metastatic melanoma, as well as resistance to targeted therapies in breast cancer, lung cancer, and other solid tumors to identify
novel ways to treat refractory advanced cancer.
Dr. Wagle's research has made important contributions to the field of personalized oncology and resistance to targeted therapeutics.
Visit Dr. Wagle's lab website
Scott Carter, PhD
Scott Carter, PhD, works closely with Boston-area physicians to design and execute studies of cancer initiation, drug resistance, and metastasis using genomics technology applied to cancer-tissue specimens collected at various stages of disease progression.
He has developed several novel computational methods to analyze these data sets and make inferences about clonal evolution underlying cancer progression. Dr. Carter has also developed software tools that are significantly increasing the impact of
his work by making those methods available to the broader research community. These tools include HAPSEG, ABSOLUTE, CapSeg, Allelic CapSeg, and Phylogic.
View Dr. Carter's Harvard Catalyst Profile
Oliver Jonas, PhD
Oliver Jonas, PhD, developed microdevices that are implanted directly into tumors and measure how the tumor responds to 30 different chemotherapies. These devices carry microdoses of each therapy, which are released into small, confined regions of tumor.
Each therapy interacts with the tumor in its native microenvironment. The effect of each therapy is then assessed using a variety of readouts, including immunohistochemistry, mass spectrometry and RNAseq. These data can then be used to identify which
therapy works optimally for a given patient.
Visit Dr. Jonas's lab website
Jens Lohr, MD, PhD
Jens Lohr, MD, PhD, is an instructor in Medicine at Harvard Medical School and a medical oncologist at Dana-Farber/Partners Cancer Care. His research focuses on how "blood biopsy" can be exploited for diagnosis,
and as a predictive and prognostic marker in patients with cancer. He uses massively parallel sequencing for the characterization of circulating tumor cells (CTCs), cell-free DNA, and exosomes. These approaches will lead to better understanding of
the dynamic molecular and genetic changes of cancer over time, which will be crucial for effective precision medicine. He is using these approaches to decipher molecular mechanisms of drug resistance, simply from a vial of blood.
Dr. Lohr obtained his MD degree from Ruprecht-Karls University in Heidelberg, Germany, where he also obtained training as an immunologist. He completed a residency in internal medicine at UCSF before coming to Boston to complete a medical oncology fellowship
in the Dana-Farber/Partners Cancer Care program.
Visit Dr. Lohr's lab website
Asaf Rotem, PhD
Prior to assuming his position as associate director of the center, Asaf Rotem, PhD, was head of the Innovation Laboratory at the Center for Cancer Precision Medicine at Dana-Farber. Under his leadership, the laboratory focused on innovative technologies
aiming to study genomics, resistance, and vulnerability of tumors derived from individual patients. He helped develop technology that allowed the testing of several anti-cancer drugs on patient-derived tumor cells to match the best drug to an individual.
Practicing this technology, Dr. Rotem found genes that contribute to cancer, and drugs that might target cancer cells in a specific manner.
Dr. Rotem completed his graduate studies at the Weizmann Institute and the Technion in Israel. He has been involved in the establishment of companies, has been a consultant, and has served on a board of directors. He held a post-doctoral research fellow
position at Harvard Medical School and was an instructor in Biological Chemistry and Molecular Pharmacology.
View Dr. Rotem's PubMed page
Sébastien Vigneau, PhD
Head of Innovation Lab
Sébastien Vigneau, PhD, joined the Center for Cancer Precision Medicine (CCPM) in 2018 as the head of the Innovation Lab. His previous background and expertise are in developmental and molecular biology, epigenetics, and bioinformatics. He completed his
PhD on X chromosome inactivation at the Pasteur Institute in Paris, after which he moved to Philadelphia to study genomic imprinting and gene expression regulation at the University of Pennsylvania. Since 2013, he has been at Dana-Farber Cancer Institute,
where his main research interests have been gene expression, single-cell RNA sequencing, and cancer.
As head of the CCPM Innovation Lab, Dr. Vigneau is leading efforts to map gene expression and cell type composition in various types of tumors, with the aim of discovering mechanisms that can be exploited to treat cancer. In parallel, he is also engaged
in the development of new technologies that will make this research effort more efficient.
View Dr. Vigneau's Harvard Catalyst Profile
Mike Cuoco, BS
Laura DelloStritto, MPH
Research Project Manager
Karla Helvie, MA
Senior Research Project Manager
Colin Mackichan, BS
Senior Pathology Technician
Angie Mayorga, BA
Research Project Manager
Allison McHenry Frangieh, MS, MPH
Research Project Manager
Sara Napolitano, BS
Rebecca Ortiz, BS
Miraj Patel, MS
Lead Pathology Technician
Shreevidya Periyasamy, BS
Nichole Straub, BS
Isaac Wakiro, BS
Jingyi Wu, BS